Astria shareholders approve BioCryst acquisition

Astria Therapeutics Inc. (NASDAQ: ATXS) announced that its stockholders voted to approve the acquisition by BioCryst Pharmaceuticals Inc. at a special meeting held January 21, 2026.

The merger is expected to close on or about January 23, 2026, subject to customary closing conditions, according to the company's statement.

Astria Therapeutics is a biopharmaceutical company focused on therapies for allergic and immunologic diseases. The company's lead program, navenibart, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema treatment. Its second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for atopic dermatitis treatment.

The information is based on a press release from Astria Therapeutics.

You May Also Be Interested In

• M3-Brigade cancels shareholder meeting after terminating ReserveOne deal
• DoJ approves Paramount's acquisition of Warner Bros - Politico
• AMETEK secures $7.5 billion in credit facilities for Indicor acquisition